Brittany Lovely

November 10, 2022

During the 40th Annual Chemotherapy Foundation Symposium®, Hope S. Rugo, MD, FASCO, outlined key priorities for the future of breast cancer research.

September 17, 2022

After 10 months of follow-up, the confirmed objective response rate among patients with metastatic gastric cancer or gastroesophageal junction adenocarcinoma who received trastuzumab deruxtecan was 41.8%.

August 06, 2022

The FDA has scheduled 3 sessions for the Oncologic Drugs Advisory Committee to review updates on the new drug application for poziotinib tablets and data for the continued approval of indications for melphalan flufenamide and duvelisib.

July 26, 2022

Based on data from the DESTINY-Breast04 trial, the FDA has granted a priority review designation for the supplemental biologics license application for fam-trastuzumab deruxtecan-nxki.

July 12, 2022

Patients with breast cancer who experience adjuvant hormone therapy (AHT)-related hot flashes and are treated for hot flashes at the beginning of therapy had worse outcomes than those who did not.

July 10, 2022

Data from the phase 2 MOUNTAINEER trial showed durable responses with tucatinib plus trastuzumab for patients with previously treated metastatic HER2-positive colorectal cancer.

July 08, 2022

Engagement with patient-reported outcome assessments, digital education tools, and patient portal information highlighted disparities in care according to data from community practices.

July 05, 2022

Nurse navigators may play a key role in mitigating toxicities from chemotherapy and perform geriatric assessments for patients treated at hematology/oncology clinics.

June 24, 2022

Updated data from the phase 3 BELIEVE trial revealed a sustained reduction in the need for red blood cell transfusions among patients with β-thalassemia who received treatment with luspatercept-aamt.

June 22, 2022

Heavily pretreated pediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia maintained response with tisagenlecelucel according to long-term follow-up data from the phase 2 ELIANA trial.